Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

NCT05443724 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05443724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05443724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Terminated
Start date
September 1, 2022
Completion date
June 25, 2025
Enrollment
698 (actual)
Sites
85

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia